Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 1
Submit an article Journal homepage
247
Views
12
CrossRef citations to date
0
Altmetric
Letter to the Editor

Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma

Dominic P. DeckerThe Warren Alpert Medical School of Brown University, Providence, RI, USA; ;Department of Medicine, Rhode Island Hospital, Providence, RI, USA; View further author information
,
Pamela C. EganThe Warren Alpert Medical School of Brown University, Providence, RI, USA; ;Department of Medicine, Rhode Island Hospital, Providence, RI, USA; ;Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI, USA; ORCID Iconhttp://orcid.org/0000-0001-8590-2916View further author information
ORCID Icon,
Adam S. ZayacThe Warren Alpert Medical School of Brown University, Providence, RI, USA; ;Department of Medicine, Rhode Island Hospital, Providence, RI, USA; ;Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI, USA; ORCID Iconhttp://orcid.org/0000-0002-7591-2069View further author information
ORCID Icon,
Diana O. TreabaThe Warren Alpert Medical School of Brown University, Providence, RI, USA; ;Department of Pathology, Rhode Island Hospital, Providence, RI, USAORCID Iconhttp://orcid.org/0000-0002-7346-9219View further author information
ORCID Icon &
Adam J. OlszewskiThe Warren Alpert Medical School of Brown University, Providence, RI, USA; ;Department of Medicine, Rhode Island Hospital, Providence, RI, USA; ;Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI, USA; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-6472-6658View further author information
ORCID Icon
Pages 198-201 | Received 11 Jun 2019, Accepted 01 Aug 2019, Published online: 21 Aug 2019

References

  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
  • Lacasce A, Howard O, Li S, et al. Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004;45:761–767.
  • Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569–1580.
  • Perry AM, Crockett D, Dave BJ, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: study of 39 cases. Br J Haematol. 2013;162:40–49.
  • Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013;369:1915–1925.
  • Roschewski M, Dunleavy K, Abramson JS, et al. Risk-adapted therapy in adults with Burkitt lymphoma: results of NCI 9177, a multicenter prospective phase II Study of DA-EPOCH-R. Blood. 2017;130:188–188.
  • Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5:e609–e617.
  • Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37:1790–1799.
  • Landsburg DJ, Falkiewicz MK, Maly J, et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. J Clin Oncol. 2017;35:2260–2267.
  • Ollila TA, Olszewski AJ. Extranodal diffuse large B cell lymphoma: molecular features, prognosis, and risk of central nervous system recurrence. Curr Treat Options Oncol. 2018;19:38.
  • Roschewski M, Dunleavy K. Secondary diffuse large B-cell lymphoma of the central nervous system: the need for better predictors. Leuk Lymphoma. 2015;56:1583–1584.
  • Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34:3150–3156.
  • Nijland M, Jansen A, Doorduijn JK, et al. Treatment of initial parenchymal central nervous system involvement in systemic aggressive B-cell lymphoma. Leuk Lymphoma. 2017;58:1–6.
  • Ennishi D, Jiang A, Boyle M, et al. Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:190–201.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.